Tocilizumab FDA Approved for COVID-19 in Hospitalized Adults
Genentech recently announced that the FDA approved Actemra (tocilizumab) for the treatment of COVID-19 in hospitalized adult patients who are receiving systemic corticosteroids and require supplemental oxygen, noninvasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation. Actemra is the first FDA-approved monoclonal antibody to treat COVID-19 and is recommended for use as a single 60-minute IV infusion. Read more.

Use of Nirmatrelvir With Ritonavir for Early COVID-19
Data from the Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients trial revealed that the use of nirmatrelvir plus ritonavir resulted in an 89% decrease in hospitalization or death among unvaccinated outpatients with early COVID-19; however, the clinical impact of nirmatrelvir plus ritonavir among vaccinated populations was unknown. Learn more about the results of this study.

Interleukin-6 Receptor Antagonists, Antiplatelets Use in COVID-19 Patients
According to a recent study, among critically ill patients with COVID-19 randomized to receive one or more therapeutic interventions there was a probability of improved 180-day mortality among patients treated with interleukin-6 receptor antagonists and antiplatelet agents. Learn more about this study aimed to ascertain the effect of multiple interventions for critically ill adults with COVID-19 on longer-term outcomes.